Sionna Therapeutics, Inc. (SION) forty fourth Annual J.P. Morgan Healthcare Convention January 13, 2026 12:45 PM EST
Firm Contributors
Michael Cloonan – President, CEO & Director
Charlotte McKee – Chief Medical Officer
Elena Ridloff – Chief Monetary Officer
Convention Name Contributors
Bhavana Balakrishnan
Presentation
Bhavana Balakrishnan
Good morning, all people. Thanks a lot for becoming a member of us right here on Day 2 of the JPMorgan Healthcare Convention. My title is Bhavana Balakrishnan. I’m an affiliate with the Healthcare Funding Banking crew. Thanks for becoming a member of us right here for the presentation of Sionna Therapeutics. With us, we now have Mike Cloonan, President and Chief Government Officer; Elena Ridloff, Chief Monetary Officer; and Charlotte McKee, Chief Medical Officer. Over to you, Mike.
Michael Cloonan
President, CEO & Director
Thanks a lot. Nice to see all people. Thanks all for attending at the moment. It is a pleasure to be with you, and thanks, JPMorgan, for the chance to current. These are our disclosures. We’ll make forward-looking statements at the moment, precise outcomes could differ from these statements. Sionna, as chances are you’ll know, is on a mission to revolutionize the therapy paradigm in CF by leveraging our first-in-class NBD1 stabilizers in combos which have the potential to drive clinically significant profit above the usual of care. Now we have a wealthy historical past, despite the fact that we have been solely shaped as an organization in late 2019, we have been a spinout from Sanofi at the moment however the science behind our applications originated at Genzyme over 15 years in the past, and that is an vital a part of the story as a result of we would not be the place we’re at the moment going after this very difficult goal in NBD1 with out the extent of perseverance and funding that was made between Genzyme and Sanofi.
We’re rather well positioned at this level to positively disrupt the CF market with
